148 related articles for article (PubMed ID: 29191854)
1. Intended Versus Inferred Treatment After
Hillner BE; Hanna L; Makineni R; Duan F; Shields AF; Subramaniam RM; Gareen I; Siegel BA
J Nucl Med; 2018 Mar; 59(3):421-426. PubMed ID: 29191854
[TBL] [Abstract][Full Text] [Related]
2. Hospice Admission and Survival After
Gareen IF; Hillner BE; Hanna L; Makineni R; Duan F; Shields AF; Subramaniam RM; Siegel BA
J Nucl Med; 2018 Mar; 59(3):427-433. PubMed ID: 29284672
[TBL] [Abstract][Full Text] [Related]
3. Impact of (18)F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Shields AF; Quinn B; Coleman RE
J Nucl Med; 2014 Jul; 55(7):1054-61. PubMed ID: 24819422
[TBL] [Abstract][Full Text] [Related]
4. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Shields AF; Coleman RE
J Nucl Med; 2014 Apr; 55(4):574-81. PubMed ID: 24578240
[TBL] [Abstract][Full Text] [Related]
5. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Quinn B; Shields AF
J Nucl Med; 2015 Feb; 56(2):222-8. PubMed ID: 25593113
[TBL] [Abstract][Full Text] [Related]
6. Intended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry.
Hillner BE; Tosteson TD; Tosteson AN; Wang Q; Song Y; Onega T; Hanna LG; Siegel BA
Med Care; 2013 Apr; 51(4):361-7. PubMed ID: 23481033
[TBL] [Abstract][Full Text] [Related]
7. Intended versus inferred care after PET performed for initial staging in the National Oncologic PET Registry.
Hillner BE; Tosteson AN; Tosteson TD; Wang Q; Song Y; Hanna LG; Siegel BA
J Nucl Med; 2013 Dec; 54(12):2024-31. PubMed ID: 24221994
[TBL] [Abstract][Full Text] [Related]
8. Prospective comparative study of
Fonager RF; Zacho HD; Langkilde NC; Fledelius J; Ejlersen JA; Hendel HW; Haarmark C; Moe M; Mortensen JC; Jochumsen MR; Petersen LJ
Acta Oncol; 2018 Aug; 57(8):1063-1069. PubMed ID: 29447047
[TBL] [Abstract][Full Text] [Related]
9. Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts.
Hillner BE; Siegel BA; Hanna L; Shields AF; Duan F; Gareen IF; Quinn B; Coleman RE
J Nucl Med; 2012 May; 53(5):831-7. PubMed ID: 22448033
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of extraskeletal computed tomography findings on 18F-NaF PET/CT performed for osseous metastatic disease evaluation.
Guo HH; Moradi F; Iagaru A
Nucl Med Commun; 2016 Sep; 37(9):975-82. PubMed ID: 27111100
[TBL] [Abstract][Full Text] [Related]
11. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Liu D; Shields AF; Gareen IF; Hanna L; Stine SH; Coleman RE
J Clin Oncol; 2008 May; 26(13):2155-61. PubMed ID: 18362365
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Assessment of Early [
Harmon SA; Perk T; Lin C; Eickhoff J; Choyke PL; Dahut WL; Apolo AB; Humm JL; Larson SM; Morris MJ; Liu G; Jeraj R
J Clin Oncol; 2017 Aug; 35(24):2829-2837. PubMed ID: 28654366
[TBL] [Abstract][Full Text] [Related]
13.
Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of 18F-NaF PET/CT in bone metastasis detection and its effect on patient management in patients with breast carcinoma.
Broos WAM; van der Zant FM; Wondergem M; Knol RJJ
Nucl Med Commun; 2018 Apr; 39(4):325-333. PubMed ID: 29351123
[TBL] [Abstract][Full Text] [Related]
15. A Prospective Study Comparing
Löfgren J; Mortensen J; Rasmussen SH; Madsen C; Loft A; Hansen AE; Oturai P; Jensen KE; Mørk ML; Reichkendler M; Højgaard L; Fischer BM
J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
[TBL] [Abstract][Full Text] [Related]
16. Technical feasibility, radiation dosimetry and clinical use of
Usmani S; Van den Wyngaert T; Ahmed N; Marafi F; Esmail A; Al Kandari F; Al Nuaimi M; Gnanasegaran G
Ann Nucl Med; 2018 Nov; 32(9):594-601. PubMed ID: 30019285
[TBL] [Abstract][Full Text] [Related]
17. The Role of 18F-Sodium Fluoride PET/CT Bone Scans in the Diagnosis of Metastatic Bone Disease from Breast and Prostate Cancer.
Kulshrestha RK; Vinjamuri S; England A; Nightingale J; Hogg P
J Nucl Med Technol; 2016 Dec; 44(4):217-222. PubMed ID: 27634981
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Challenge of Staging Metastatic Bone Disease in the Morbidly Obese Patients: A Primary Study Evaluating the Usefulness of 18F-Sodium Fluoride (NaF) PET-CT.
Usmani S; Marafi F; Ahmed N; Esmail A; Al Kandari F; Van den Wyngaert T
Clin Nucl Med; 2017 Nov; 42(11):829-836. PubMed ID: 28872551
[TBL] [Abstract][Full Text] [Related]
19. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
BJU Int; 2012 Nov; 110(10):1501-6. PubMed ID: 22502982
[TBL] [Abstract][Full Text] [Related]
20. Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice.
Bastawrous S; Bhargava P; Behnia F; Djang DS; Haseley DR
Radiographics; 2014; 34(5):1295-316. PubMed ID: 25208282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
